Back to Results

Nicotinic agonist effects on BMI and neuronal response in overweight/obese adults

Primary Objective

This research study plans to examine the effects of an investigational new drug on neuronal, physiological, and behavioral mechanisms of obesity in the general population.

Study category: Nutrition and Metabolism

Is this Study for You?

Let's Get Started!

Description

This study plans to learn more about the effects of an investigational new drug (DMXB-A) and its effects on obesity. The study drug has similar effects to nicotine. Since nicotine has been found to effect appetite, we are interested in studying the effects of the study drug, which has similarities to nicotine, on how your brain responds to such things as pictures of food. This study drug has not been approved by the Food and Drug Administration (FDA), and is considered experimental.

Details
Age

Adult

Eligibility

BMI greater than 27; Be 21-65 years old; Have no known cardiovascular disease; Be a non-smoker; Not be pregnant or trying to conceive; Be able to complete an MRI scan.

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Basic Science

Location

University of Colorado Hospital

Principal Investigator
Jason Tregellas

Jason Tregellas

Study ID

Protocol Number: 15-0650

More information available at ClinicalTrials.gov: NCT02458313

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers